Traws Pharma, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Traws Pharma, Inc. (TRAW) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $2.93 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-04-15
- Traws Pharma, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $2.93M.
- Traws Pharma, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was -$137.45M, a 3406.52% decline from fiscal 2023.
- Traws Pharma, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $4.16M, a 11.75% increase from fiscal 2022.
- Traws Pharma, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $3.72M, a 32.49% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $2.93M 10-K · filed 2026-04-15 |
| 2024-12-31 | -$137.45M 10-K · filed 2026-04-15 |
| 2023-12-31 | $4.16M 10-K · filed 2025-03-31 |
| 2022-12-31 | $3.72M 10-K · filed 2024-04-01 |
| 2021-12-31 | $5.51M 10-K · filed 2023-03-30 |
| 2020-12-31 | $7.32M 10-K · filed 2022-03-21 |
| 2019-12-31 | $9.09M 10-K · filed 2021-03-18 |
| 2018-12-31 | $7.56M 10-K · filed 2020-03-27 |
| 2017-12-31 | -$13.43M 10-K · filed 2019-04-01 |
| 2016-12-31 | $8.74M 10-K · filed 2018-03-16 |
| 2015-12-31 | $17.12M 10-K · filed 2017-03-29 |
| 2014-12-31 | $38.65M 10-K · filed 2016-03-28 |
| 2013-12-31 | $38.01M 10-K · filed 2015-03-30 |
| 2012-12-31 | $8.72M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |